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Abstract: The American Diabetes Association and The European Association for the Study of 
Diabetes recommend metformin as the initial agent of choice in the treatment of type 2 diabetes 
mellitus. Unfortunately, most patients require multiple medications to obtain glycemic control. 
One of the newest additions to the antidiabetic armamentarium is the class of drugs known as 
dipeptidyl-peptidase IV (DPP-IV) inhibitors. This novel approach focuses on harnessing the 
beneficial effects of GLP-1, an incretin hormone released from the gut postprandially. The 
first DPP-IV inhibitor approved in the United States was sitagliptin. It has been studied in both 
monotherapy and combination therapy. Combination studies with metformin realize a hemo-
globin A1c reduction of 0.65%–1.1%. The combination of the two has a modest positive effect 
on body weight with the convenience of an oral route of administration. It has also been shown 
to be highly tolerable, efficacious and with little risk of hypoglycemia. This review will focus 
on combination therapy with sitagliptin with emphasis on combination with metformin.
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Introduction
According to current estimates, type 2 diabetes mellitus (T2DM) affects approximately 
21 million Americans.1 Insulin resistance, the primary defect present in T2DM, is mainly 
due to genetic and lifestyle factors. Current treatment strategies focus on lifestyle changes, 
reducing hyperglycemia, and improving insulin sensitivity. Weight loss and oral medica-
tions improve insulin sensitivity and lower blood glucose by decreasing insulin resistance. 
Other agents including insulin secretagogues, biguanides, insulin analogs, and dipeptidyl 
peptidase (DPP-IV) inhibitors also reduce blood glucose, through diverse mechanisms. 
Despite this wide array of treatment options, most patients remain above goal.
Sitagliptin, a DPP-IV inhibitor, helps the body take advantage of the incretin hormone 
glucagon-like peptide (GLP-1). GLP-1 is released from the gastrointestinal tract in response 
to a meal. When blood glucose is elevated, GLP-1 stimulates insulin secretion. In addition, 
GLP-1 reduces glucagon secretion, slows gastric emptying, and appears to regulate the 
growth of insulin producing β-cells (Figure 1).2 GLP-1 is rapidly inactivated by the DPP-IV 
enzyme.3 By inhibiting DPP-IV, the positive effects of GLP-1 are prolonged. This article 
reviews publications and abstracts involving combination therapy with sitagliptin. These 
trials should provide greater insight into sitagliptin’s role in combination therapy.
Pharmacology
Experts have identified multiple signals leading from the gastrointestinal tract to 
the pancreas.4 An experiment first described in the 1960s compared the metabolic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 24
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response to a glucose load delivered intravenously versus 
orally. Levels of serum glucose appeared similar; however 
the plasma insulin response evoked from the oral glucose 
load was far greater. In other words, the intravenous glucose 
load provided a suboptimal insulin response when compared 
to an oral glucose load. This has been termed the incretin 
effect; the majority of its effect modulated by the incretin 
hormones GLP-1 and glucose-dependent insulinotropic 
peptide (GIP).
An incretin is a hormone that is released from the gut 
in response to nutrients (mainly carbohydrates), stimulates 
insulin release in response to a meal, and causes insulin 
release in a glucose dependent manner.4 The gastrointestinal 
hormone GLP-1 is quickly inactivated by the DPP-IV 
enzyme. DPP-IV is found in the kidneys, intestines, and bone 
marrow with lower concentrations in the liver, pancreas, 
placenta, thymus, spleen, epithelial cells, vascular endothe-
lium, and lymphoid and myeloid cells.2,5
Patients with T2DM have been shown to have reduced 
concentrations of intact GLP-1. Vilsboll et al conducted 
a study involving 12 subjects with T2DM and 12 healthy 
controls.6 Blood samples were collected at 15, 30, 45, 
60, 75, 90, 120, 150, and 180 minutes postprandially 
to determine intact GLP-1 concentrations. GLP-1 
concentrations were lower in patients with diabetes 75, 
90, and 120 minutes after meal ingestion (p = 0.056, 
0.017, and 0.017, respectively). In addition, insulin and 
C-peptide concentrations were decreased during these same 
time periods, indicating an abnormal insulin response. 
The investigators concluded that in the absence of normal 
concentrations of intact GLP-1, the insulin response in 
patients with T2DM is blunted.
Kinetics
The oral bioavailability of sitagliptin is 87% with a terminal 
half-life of 10 to 12 hours. Median time to maximum 
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Glucose-dependent
insulin biosynthesis
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Figure 1 The role of glucagon-like peptide (GLP-1) in glucose homeostasis. reprinted with permission from weber A. Dipeptidyl peptidase iv inhibitors for the treatment of 
diabetes.  J Med Chem. 2004;47:4135–4141.2 Copyright © American Chemical Society.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 25
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concentration (Tmax) is 1 to 6 hours and varies across 
the dosing range; sitagliptin is excreted primarily by the 
kidneys.7,8 Neither the absorption, Tmax, nor the half-life 
are significantly altered when sitagliptin is administered 
with food. Although sitagliptin is a minor substrate for the 
CYP450 system, it is not an inhibitor or inducer of this 
system.7 The apparent volume of distribution is 198 L and 
sitagliptin has been reported to be 38% bound to plasma 
proteins.7
Clinical trials
Sitagliptin has been studied with metformin, glipizide, 
glimepiride and pioglitazone (Table 1). One of the 
first studies to address sitagliptin as add-on therapy to 
metformin in patients with inadequate glycemic control 
was conducted by Brazg and colleagues.9 In this double-
blind, randomized, placebo-controlled, cross-over study, 
28 patients (baseline HgbA1c [A1c] ranging from 6.5% to 
9%) received sitagliptin 50 mg twice daily or placebo for 
4 weeks followed by the opposite treatment for an additional 
4 weeks. The primary endpoint analyzed was 24-hour 
weighted mean glucose (WMG); secondary endpoints 
included fasting plasma glucose (FPG) and fructosamine. 
There was a significant least-squares mean reduction in 
WMG, FPG and fructosamine (32.8 mg/dL, 20.3 mg/dL, 
and 33.7 mmol/L, respectively). The addition of sitagliptin 
did not lead to additional adverse events compared to 
metformin monotherapy. This short term study highlighted 
the efficacy and tolerability of combination therapy with 
metformin and sitagliptin.
A 24-week study conducted by Goldstein, et al assessed 
the effect of adding sitagliptin and metformin in 1091 
patients inadequately controlled on diet and exercise alone.10 
This double-blind, placebo-controlled, parallel-group study 
randomized patients to one of six treatment groups: sitagliptin 
100 mg + metformin 1000 mg, sitagliptin 100 mg + metformin 
2000 mg, metformin 1000 mg, metformin 2000 mg, 
sitagliptin 100 mg, or placebo. The mean baseline A1c was 
8.8%. The placebo subtracted changes in A1c after 24 weeks 
of treatment were 2.07%, 1.57%, 1.3%, 0.99%, and 0.83% 
for the sitagliptin 100 mg + metformin 1000 mg, sitagliptin 
100 mg + metformin 2000 mg, metformin 1000 mg, 
metformin 2000 mg, and sitagliptin 100 mg groups, 
respectively (p  0.001 for all comparisons versus placebo). 
The incidence of hypoglycemia reported was low (0.5% 
to 2.2%) and similar to placebo (0.6%); sitagliptin did not 
appear to increase gastrointestinal adverse events associated 
with metformin use. The authors concluded combination 
therapy with metformin and sitagliptin provides additive 
glycemic benefit and is generally well tolerated.
Charbonnel et al conducted a 24-week randomized, 
double-blind, parallel-group study in 701 patients.11 This 
study assessed the safety and efficacy of adding sitagliptin 
to ongoing metformin therapy (1500 mg/day) in patients 
with a mean A1c of 8.0%. Patients were randomized to 
receive sitagliptin 100 mg daily or placebo. At study end, 
sitagliptin treatment produced a significant reduction in 
A1c (0.65%, p  0.001), and FPG (25.4 mg/dL, p  0.001). 
No increase in the incidence of gastrointestinal events was 
noted and hypoglycemia rates between groups were similar. 
Nasopharyngitis, urinary tract infection, arthralgia, back 
pain and cough were all experienced at a higher incidence 
in the sitagliptin group compared to placebo. Body weight 
remained neutral. The authors concluded that sitagliptin 
100 mg once daily was well tolerated and provided sustained 
improvements in A1c and FPG in patients inadequately 
controlled on metformin monotherapy. A 30-week exten-
sion was then conducted.12 Patients initially treated with 
sitagliptin remained on the drug, while patients taking 
placebo were switched to glipizde 5 mg daily (titrated to a 
maximum dose of 15 mg/day). Of the original 701 patients 
randomized, 544 patients continued with this portion of the 
study (sitagliptin n = 387, glipizide n = 157). For patients 
already on sitagliptin, the A1c did not change significantly 
from week 24 to week 52 (–0.07%). The change in A1c from 
baseline was -0.7% (p-value not reported) in the sitagliptin 
arm and -0.9% (p-value not reported) in the glipizide arm. 
Hypoglycemia was reported more in the glipizide group 
compared to sitagliptin (16% versus 1%, respectively). 
The sitagliptin group experienced a weight reduction of 
0.9 kg from baseline; conversely, patients in the glipizide 
arm recorded a weight gain of 1.5 kg.
In a long term trial, Nauck and colleagues conducted 
a non-inferiority study to compare the effects of adding 
sitagliptin or glipizide to patients uncontrolled on metformin 
monotherapy (mean baseline A1c 7.5%).13 Patients were 
randomized to receive sitagliptin (n = 588) 100 mg daily 
or glipizide (n = 584) 5 mg daily (titrated to a maximum 
of 20 mg daily) for 52 weeks. The primary endpoint was 
defined as the change in A1c from baseline. A1c changes 
from baseline were –0.67% for both groups, confirming non-
inferiority of sitagliptin. Fasting plasma glucose decreased 
from baseline in the sitagliptin group (10.0 mg/dL, p-value 
not reported) as well as the glipizide group (7.5 mg/dL, 
p-value not reported). More patients in the glipizide group 
experienced hypoglycemia (32%, p  0.001) compared to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 26
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sitagliptin (5%, p  0.001). Body weight was reduced with 
sitagliptin (1.5 kg, p  0.001), compared with weight gain in 
the glipizide arm (1.1 kg, p  0.001). The authors concluded 
that sitagliptin is comparable to glipizide in glycemic control 
but free from significant hypoglycemia and weight gain.
The safety and efficacy of sitagliptin addition was studied 
in a 24-week, randomized, double-blind trial in patients 
inadequately controlled on glimepride with or without 
metformin.14 Patients were randomized to receive the addition 
of sitagliptin 100 mg daily or placebo (212 on glimepiride, 229 
on glimepiride and metformin). After 24 weeks, sitagliptin 
reduced the A1c by 0.74% (p  0.001) in the overall random-
ized cohort of patients. In the subset of patients receiving 
metformin and glimepiride, the largest A1c reduction was 
noted (0.89%, p-value not reported), compared to the subset of 
patients on glimepiride alone (–0.57%, p-value not reported). 
Fasting and postprandial blood glucose also improved with the 
addition of sitagliptin. Hypoglycemia was higher in the sita-
gliptin group compared to placebo (12% vs 2%, p  0.001); 
however, no episodes required medical attention. At study 
end, the placebo-adjusted body weight was increased in the 
sitagliptin arm (1.1 kg, p  0.001).
The combination of sitagliptin and pioglitazone was 
explored in a 24-week, double-blind, placebo-controlled, 
parallel-group study.15 In this study, 353 patients on piogli-
tazone monotherapy (30 or 45 mg/daily) were randomized 
to receive either the addition of sitagliptin 100 mg daily or 
placebo. The primary efficacy end point was change in A1c 
from baseline to study end. Fasting plasma glucose was 
a secondary end point. The addition of sitagliptin signifi-
cantly reduced A1c with a between-treatment difference of 
0.7% (p  0.001). Fasting plasma glucose also decreased 
by 17.7 mg/dL (p  0.001). The proportion of patients 
able to reach an A1c of 7% was 45.4% in the sitagliptin 
group versus 23.0% in the placebo group. The sitagliptin 
plus pioglitazone group experienced a higher incidence of 
gastrointestinal adverse effects than placebo (13.7% vs 6.2%, 
respectively). No significant difference in hypoglycemia was 
observed. Both groups experienced one episode of edema; 
no reports of congestive heart failure were observed. The 
authors concluded that the combination of sitagliptin plus 
pioglitazone is well tolerated and significantly improves 
glycemic control.
Clinical trial limitations
Findings discussed in the above trials are limited to specific 
populations enrolled in each trial. To date, most of the clinical 
trials involving sitagliptin combination therapy are limited to 
metformin. Additional studies involving combination therapy 
with sitagliptin and other antihyperglycemic agents are 
needed in order to make recommendations regarding optimal 
combination therapy. Also, the efficacy and safety of sita-
gliptin combination therapy has not been evaluated beyond 
one year; future trials of longer duration will be needed to 
define its role. Given sitagliptin’s potential to affect disease 
progression, effects on microvascular and macrovascular 
outcomes should also be explored.
Adverse events
The most common adverse events associated with sitagliptin 
include nasopharyngitis, upper respiratory tract infection, 
and headache. Other adverse events reported with sitagliptin 
include abdominal pain, nausea, diarrhea, and vomiting; 
however, the incidence of these adverse events are similar 
to placebo.7 In clinical trials sitagliptin has not been associ-
ated with any significant changes in complete blood counts, 
transaminase and serum creatinine levels, vital signs, or 
electrocardiogram.7 It is important to note, however, that 
hypersensitivity reactions such as anaphylaxis, angioedema, 
and Stevens-Johnson syndrome have been reported during 
post-marketing surveillance.16
Hypoglycemia, an adverse event that plagues several of 
the other available treatments for T2DM, is not significant 
with sitagliptin therapy. In fact, a pooled analysis of four 
studies showed that the incidence of hypoglycemia was 1.2%, 
0.9%, and 0.9% with sitagliptin 100 mg, sitagliptin 200 mg, 
and placebo, respectively.8
Weight gain is another adverse event of concern to 
practitioners treating T2DM. Treatment with sitagliptin has 
shown variable results. Monotherapy studies with sitagliptin 
showed a small reduction in weight; however, a greater 
reduction was experienced by the placebo groups. When 
combined with metformin or pioglitazone, weight changes 
were similar relative to placebo. Sitagliptin in combination 
with sulfonylureas led to a significant weight increase when 
compared to the placebo groups.8
Drug interactions
Sitagliptin appears to be well tolerated with a marginal drug 
interaction profile. It is a minor substrate of the CYP450 
system, but is not an inhibitor or inducer of any of the 
isoenzymes.7 Sitagliptin is not extensively bound to plasma 
proteins.7 Subsequently, the probability of sitagliptin being 
involved in clinically meaningful drug-drug interactions 
mediated by protein plasma binding is quite low. The 
combination of sitagliptin and metformin when co-admin-Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 28
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istered does not extensively alter the pharmacokinetics of 
either agent.17 Sitagliptin has been found to increase the 
area under the curve (AUC) and plasma concentration 
of digoxin; however, no dosage adjustment is required.18 
When administered with cyclosporine, drug exposure and 
peak concentrations of sitagliptin are increased; therefore, a 
dose reduction of sitagliptin may be warranted and careful 
monitoring should be conducted.18
Dosing and administration
The recommended starting dose for sitagliptin is 100 mg 
daily. Sitagliptin can be given without regards to meals. 
The dose should be reduced to 50 mg daily with a creatinine 
clearance (CrCl) of 30 to 50 mL/min and to 25 mg daily with 
CrCl less than 30 mL/min.7 Patients with T2DM less than 
18 years of age should not receive sitagliptin. Sitagliptin is 
considered pregnancy category B; it is unknown whether 
sitagliptin is excreted into breast milk. A dose adjustment is 
not required in geriatric patients; however, caution should 
be exercised when using sitagliptin in patients who are over 
75 years of age.18
Numerous clinical trials with the combination of sita-
gliptin and metformin have led to the development of 
Janumet™ (Merck and Co., Inc.), the only commercially 
available combination product with the aforementioned 
agents.19 Dosing with sitagliptin and metformin should 
be individualized as dictated by efficacy and tolerability. 
The maximum recommended daily dose for metformin is 
2550 mg in divided doses; however, increasing the dose 
over 2000 mg provides marginal benefit.20 The maximum 
recommended dose of sitagliptin is 100 mg daily in a single 
or divided dose.21 Janumet™ should be started at the initial 
dose of 50/500 twice daily for patients with type 2 diabetes 
not adequately controlled on diet and exercise alone. Dosing 
may be titrated to Janumet™ 50/1000 twice daily if further 
glucose lowering is desired. For patients taking 850 mg of 
metformin twice daily, the manufacturer recommends start-
ing Janumet™ at 50/1000 mg twice daily.19 Due to the effects 
of metformin on the gastrointestinal system, the combination 
should be given with meals. Special consideration must be 
given to patients with renal insufficiency. The package insert 
of metformin suggests patients with renal disease or insuf-
ficiency as evidenced by a serum creatinine of 1.5 mg/dL 
in males or 1.4 mg/dL in females should not take metformin. 
The package insert of Janumet™ lists the same contraindi-
cations. In addition, patients undergoing radiologic studies 
involving intravascular administration of iodinated contrast 
materials should temporarily discontinue Janumet™.19
Sitagliptin has not been approved in combination 
with other antidiabetic agents. However, in clinical trials 
sitagliptin has been given in combination with glimepiride, 
glipizide and pioglitazone. If initiating sitagliptin in patients 
on sulfonylureas, the dose of the sulfonylurea may need to be 
reduced to avoid the risk of hypoglycemia.16 Sitagliptin has 
not been studied with concomitant insulin therapy.
Place in therapy
Lifestyle modifications are the cornerstone of treatment for 
T2DM and should be implemented early in the course of 
the disease. Weight loss may significantly improve glucose 
levels; unfortunately this cost effective approach is met with 
limited long-term success.22 Consequently, the majority of 
patients with type 2 diabetes require the addition of phar-
macotherapy (Table 2).
The currently available treatment options target at least 
three core defects in diabetes by improving insulin sensi-
tivity, improving insulin resistance, or impeding secretion 
of glucagon. Despite the large arsenal of drug therapies, 
choosing an appropriate treatment poses a challenge for the 
health care provider. This challenge is compounded when 
the initial therapy fails and a choice of adjunctive treatment 
must be chosen. The American Diabetes Association (ADA) 
and The European Association for the Study of Diabetes 
have developed an evidence based algorithm to guide the 
practitioner in initial as well as adjunctive treatment.24 In 
combination with lifestyle modifications, metformin should 
be implemented first line. In addition to its glucose lowering 
ability, metformin is recommended for its lack of weight gain, 
high patient tolerability, and cost. To ensure patient compli-
ance, metformin should be titrated slowly and increased to 
maximum doses over one to two months.
Patients unable to attain glycemic control (A1c  7%) 
with maximum doses of metformin should receive an addi-
tional agent. Step 2 of the algorithm advocates adding either 
insulin or a sulfonylurea.24 The A1c will determine which 
agent to add. If the A1c level is greater than 8.5%, consider-
ation is given to the addition of insulin. Initiation of insulin 
can either be intermediate acting insulin at bedtime or longer 
acting insulin given at either bedtime or in the morning. 
Conversely, adding a sulfonylurea to metformin in patients 
with a lesser degree of hyperglycemia (ie, A1c  8.5%) is 
recommended. If these choices do not produce target glyce-
mic levels, the final step is to intensify insulin treatment or 
begin insulin if not done in the previous step.
In certain populations, the algorithm recognizes other 
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an issue, addition of pioglitazone or exenatide may be 
considered. Rosiglitazone is no longer recognized in the 
consensus algorithm. Several meta-analyses have suggested 
a relative increase in the risk of myocardial infarction.25–27 
The panel decided unanimously to remove rosiglitazone 
while recognizing that the information currently available 
is not conclusive regarding the cardiovascular risk associ-
ated with rosiglitazone. Other agents are mentioned, but 
their greater expense and lack of evidence limits their use 
to special populations. This includes the class of DPP-IV 
inhibitors.
Sitagliptin was the first DPP-IV approved in 2006. 
Unlike other newer agents, pramlintide and exenatide, 
sitagliptin offers the advantage of oral administration. 
Clinical trials indicate sitagliptin is effective in both 
monotherapy and combination therapy. It has been studied 
extensively with metformin. This combination does not 
cause increased side effects or alter the pharmacokinetics 
of either agent.
Sitagliptin does not cause hypoglycemia or weight gain 
which has plagued other classes of antihyperglycemics. The 
A1c lowering of the DPP-IV inhibitor class is approximately 
0.6% to 0.9%, which is less than the first tier agents recom-
mended by the ADA. Several factors must be considered 
when deciding upon adjunctive therapy including side 
effects, route of administration, cost, and patient prefer-
ence. Clinicians should also assess the risks versus benefits 
when selecting optimal treatment. DPP-IV inhibitors may 
be most appropriate for patients experiencing hypoglycemia 
or in patients already on dual oral therapy (sulfonylurea and 
metformin) with an A1c close to goal. Although sitagliptin 
is not associated with greater glucose control compared 
with conventional therapy, it is effective, well tolerated, and 
provides sustainable reductions in A1c.
Conclusion
Type 2 diabetes mellitus is a chronic, progressive disease 
often requiring two or more medications to obtain optimal 
glucose control. With the discovery of the incretin effect 
came the emergence of a new class of drugs, the DPP-IV 
inhibitors. The exact role of sitagliptin, the prototype DPP-IV 
inhibitor, remains to be explored. Currently, the ADA recom-
mends metformin as the initial agent of choice, followed by 
sulfonylureas and insulin as preferred adjunctive therapy. 
Patients experiencing hypoglycemia on conventional therapy, 
or remaining above the desired A1c goal, may be candidates 
for sitagliptin. Evidence suggests that combining metformin 
and sitagliptin provides a positive effect on body weight and 
A1c with the convenience of oral administration. It is also 
proven to be safe, efficacious and well tolerated. Although the 
combination of sitagliptin and metformin appears effective, 
the use of this combination may be restricted by its relatively 
high cost and lack of long term safety data. Also, information 
on sitagliptin in combination with other antidiabetic agents 
is lacking.
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Table 2 Comparison of approved antidiabetic medications in the United States7,16,23
Medication Class Dosage form A1c reduction (%) Adverse effects
metformin Biguanides Oral 1.5 Gastrointestinal effects, rare 
lactic acidosisa
glipizide, glimepiride, 
glyburide
Sulfonylureas Oral 1.5 Hypoglycemia, weight gain
rosiglitazone, pioglitazone Thiazolidinediones Oral 0.8–1.0 weight gain, exacerbation of 
heart failure
nateglinide, repaglinide Meglitinides Oral 1–1.5 Hypoglycemia, weight gain
acarbose, miglitol α-glucosidase inhibitors Oral 0.5–0.8 Gastrointestinal effects
various trade names insulin Parenteral 2.5 Hypoglycemia, weight gain
pramlintide Amylinomimetics Parenteral 0.6 Gastrointestinal effects, 
hypoglycemiab
exenatide GLP-1 analog Parenteral 0.5–1.0 Gastrointestinal effects
sitagliptin DPP-iv inhibitors Oral 0.5–0.9 Nasopharyngitis, Uri, headache
aincidence in 0.03 cases per 1000 patient years.
bBlack-box warning for severe insulin-induced hypoglycemia if administered within 3 hours of insulin.
Abbreviations: A1c, glycosylated hemoglobin; DPP-iv, dipeptidyl peptidase iv; GLP, glucagon-like peptide; Uri, upper respiratory tract infection.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2
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